返回 
加入收藏
阿托伐他汀联合缬沙坦对慢性肾炎患者疗效及相关指标的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | 阿托伐他汀联合缬沙坦对慢性肾炎患者疗效及相关指标的影响 |
| TITLE： | |
| 摘要： | 目的：探讨阿托伐他汀联合缬沙坦对慢性肾炎患者疗效、安全性及相关指标的影响。方法：86例慢性肾炎患者随机分为对照组（43例）和观察组（43例）。两组患者均给予低盐、低蛋白优质饮食，蛋白质摄入量0.8 g/（kg·d），并酌情给予环磷酰胺，同时给予醋酸泼尼松、青霉素V钾等常规治疗。在此基础上，对照组患者给予缬沙坦胶囊160 mg，每日1次，晨起时服用。观察组患者在对照组治疗的基础上给予阿托伐他汀钙片20 mg，每日1次，睡前服用。两组均治疗6个月。观察两组患者的临床疗效，检测治疗前后24 h蛋白量（24 h pro）、血肌酐（Scr）、尿素氮（BUN）、肾小球滤过率（GFR）、C反应蛋白（CRP）、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL）、高密度脂蛋白（HDL）水平，并随访9个月的不良反应发生情况。结果：观察组患者总有效率显著高于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者24 h pro、Scr、BUN、GFR 、CRP、TC、TG、LDL、 HDL水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者24 h pro、Scr、BUN、CRP水平均显著低于同组治疗前，且观察组低于对照组，GFR水平显著高于同组治疗前，且观察组高于对照组，差异均有统计学意义（P＜0.05）。两组患者TC、LDL水平均显著低于同组治疗前，HDL水平显著高于同组治疗前，差异均有统计学意义（P＜0.05）；但两组间及两组治疗前后TG水平比较，差异均无统计学意义（P＞0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。结论：在常规治疗的基础上，阿托伐他汀联合缬沙坦治疗慢性肾炎的疗效显著优于单用缬沙坦，可显著改善肾功能，且近期安全性相当。 |
| ABSTRACT： | OBJECTIVE： To investigate the effects of atorvastatin combined with valsartan on efficacy， safety and related indicators in patients with chronic nephritis. METHODS： 86 patients with chronic nephritis were randomly divided into control group （43 cases） and observation group （43 cases）. All patients were given low-salt， low-protein and high-quality diet with protein intake of 0.8 g/（kg·d）， appropriately given Cyclophosphamide tablet， Prednisone tablet， Penicillin V potassium tablet and other conventional treatment. Based on it， control group was given 160 mg valsartan， once a day in early morning. Observation group was additionally given 20 mg atorvastatin， once a day before bedtime. They were treated for 6 months. Clinical efficacy， 24 h protein amount （24 h pro）， serum creatinine （Scr）， blood urea nitrogen （BUN）， glomerular filtration rate （GFR）， C-reactive protein （CRP）， total cholesterol （TC）， triglyceride （TG ）， low density lipoprotein （LDL） and high density lipoprotein （HDL） in 2 groups were observed， and incidence of adverse reactions was followed-up for 9 months. RESULTS： The total effective rate in observation group was significantly higher than control group， the difference was statistically significant （P＜0.05）. Before treatment， there were no significant differences in 24 h pro， Scr， BUN， GFR， CRP， TC， TG， LDL and HDL between 2 groups （P＞0.05）. After treatment， 24 h pro， Scr， BUN and CRP in 2 groups were significantly lower than before， and observation group was lower than control group， GFR was significantly higher than before， and observation group was higher than control group， the differences were statistically significant （P＜0.05）. TC and LDL in 2 groups were significantly lower than before， HDL was higher than before， the differences were statistically significant （P＜0.05）； but there were no significant differences in the TG between 2 groups and before and after treatment （P＞0.05）. And there was no significant differences in the incidence of adverse reactions between 2 groups （P＞0.05）. CONCLUSIONS： Based on the conventional treatment， the efficacy of atorvastatin combined with valsartan is superior to valsartan alone in the treatment of chronic nephritis， and it can significantly improve renal functions， with similar short-term safety. |
| 期刊： | 2016年第27卷第15期 |
| 作者： | 吴潇，陈宇 |
| AUTHORS： | WU Xiao，CHEN Yu |
| 关键字： | 阿托伐他汀；缬沙坦；慢性肾炎；肾功能；疗效；安全性 |
| KEYWORDS： | Atorvastatin； Valsartan； Chronic nephritis； Renal function； Efficacy； Safety |
| 阅读数： | 302 次 |
| 本月下载数： | 4 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
